Frontera Therapeutics, a clinical-stage biotech startup with operations in both China and the US, has pocketed $160 million in a Series B round of financing to bring the total fundraising size of the three-year-old firm to $195 million.
The Series B round was jointly led by Sequoia Capital China and Chinese private equity (PE) firm Boyu Capital, with participation from global healthcare investment company OrbiMed and life science-focused venture capital (VC) firm Creacion Ventures, Frontera said in a statement on Tuesday. OrbiMed and Creacion Ventures were lead investors of its Series A round.
